| 18.56 0.73 (4.09%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 22.12 | 1-year : | 25.83 |
| Resists | First : | 18.94 | Second : | 22.12 |
| Pivot price | 15.62  |
|||
| Supports | First : | 15.22 |
Second : | 12.92 |
| MAs | MA(5) : | 17.82 |
MA(20) : | 15.41 |
| MA(100) : | 12.42 |
MA(250) : | 8.44 |
|
| MACD | MACD : | 1.1 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 87.1  |
D(3) : | 88.9 |
| RSI | RSI(14): 74.7 |
|||
| 52-week | High : | 18.94 | Low : | 3.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RLAY ] has closed below upper band by 7.1%. Bollinger Bands are 94.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 18.78 - 18.85 | 18.85 - 18.91 |
| Low: | 17.42 - 17.51 | 17.51 - 17.59 |
| Close: | 18.4 - 18.55 | 18.55 - 18.68 |
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Fri, 26 Jun 2026
Relay Therapeutics, Inc. Actuals & Estimates (NASDAQ:RLAY) - TradingView
Thu, 25 Jun 2026
RLAY Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 25 Jun 2026
Relay Therapeutics (RLAY) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Wed, 24 Jun 2026
Relay Therapeutics president R&D sells $1.58m in stock - Investing.com UK
Wed, 24 Jun 2026
Relay Therapeutics (RLAY) R&D chief exercises options and sells 93K shares - Stock Titan
Wed, 24 Jun 2026
Relay Therapeutics (NASDAQ: RLAY) CFO sells 187,163 shares after exercising options - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 218 (M) |
| Held by Insiders | 1.3602e+008 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 27,410 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.9361e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 619.6 % |
| Return on Equity (ttm) | -24.8 % |
| Qtrly Rev. Growth | 1.068e+007 % |
| Gross Profit (p.s.) | -34.8 |
| Sales Per Share | -22.87 |
| EBITDA (p.s.) | -1.40331e+008 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -213 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.82 |
| Price to Cash Flow | 9.58 |
| Dividend | 0 |
| Forward Dividend | 3.439e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|